Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system - PubMed
3 hours ago
- #Antineoplastic Agents
- #Pharmacovigilance
- #Interstitial Lung Disease
- Study analyzed FAERS reports to compare interstitial lung disease (ILD) reporting associations across antineoplastic agents in breast, ovarian, and prostate cancers.
- Trastuzumab deruxtecan (T-DXd) showed the strongest ILD signal and highest adjusted reporting association among 65 evaluated agents.
- Some sex hormone-pathway agents, like darolutamide and fulvestrant, also exhibited elevated ILD reporting associations, with older age and lower body weight identified as independent risk factors.
- Exploratory analyses indicated shorter median time-to-onset for death-recorded ILD reports, particularly in patients weighing ≥70 kg, suggesting hypothesis-generating insights.
- A literature review of 85 publications supported FAERS findings, emphasizing varied ILD risks across agents and the need for early monitoring and prospective validation.